New drug in leukaemia fight

A new anti-cancer medication has been approved by the TGA for treatment of the most common type of leukaemia in Australia Venclexta (venetoclax) is a once-daily oral B-cell lymphoma-2 inhibitor that has been approved by the TGA this month, for use by patients with harder-to-treat forms of chronic lymphocytic leukaemia. The decision is a “major milestone”